Global Barlow’s Syndrome Market Size, Share, Forecast Report, 2020-2027

Barlow’s syndrome is an abnormality of the mitral valve of the heart. It is a condition in which the leaflets of the mitral valve swell and shifts towards to the left atrium of the heart as the valve closes during ventricular contraction. This abnormality prevents the valve from closing suitably, which causes it to leak.

Barlow’s Syndrome can be caused by various reasons, some of them are calcium buildup, congenital heart defects, radiation treatment, and tumors. Additionally, traumatic injury, disease, or infection can lead to Barlow’s Syndrome.
Segments

The global Barlow’s Syndrome market is segmented on the basis of type, treatment, diagnosis, and end-users.

On the basis of the type, the market is segmented as mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.

On the basis of the treatment, the market is segmented into medications and surgery. The medications are further sub-segmented into beta-blockers and calcium blockers. Beta-blockers further sub-segmented into Atenolol and Metoprolol. Calcium blockers further sub-segmented into Verapamil and Diltiazem.

On the basis of the diagnosis, the market is segmented into X-ray, Electrocardiogram, and Echocardiogram.

On the basis of the end user, the market is segmented into hospitals & surgical centers, research institutes, and specialty clinics.
Key Players

Some of the key players in the barlows syndrome market are Abbott, Medtronic, CryoLife, Inc., Lepu Medical Technology Co., Ltd. Boston Scientific Corporation, Micro Interventional Devices, Inc., Neovasc, Inc., Edward Lifesciences Corporation, Sorin Group, TTK HealthCare, and JenaValve Technology, Inc